Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Key Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of NSCLC with EGFR mutations known to be associated with EGFR TKI sensitivity, EGFR T790M negative and MET gene amplification * Stage IIIB/IIIC or IV NSCLC * Participants must have progressed on one prior line of therapy (1st/2nd generation EGFR TKIs, osimertinib or other third generation EGFR TKIs) for advanced/metastatic disease (stage IIIB/IIIC and must be candidates for platinum (cisplatin or carboplatin) - pemetrexed doublet based chemotherapy * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 * Participants must have recovered from all toxicities related to prior systemic therapy to grade ≤ 1 Common Terminology Criteria Adverse Event 5.0 (CTCAE v 5.0) * At least one measurable lesion as defined by RECIST 1.1 * Participants must have adequate organ function Key Exclusion Criteria: * Prior treatment with any MET inhibitor or HGF-targeting therapy * Participants with symptomatic central nervous system (CNS) metastases who were neurologically unstable or had required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms * Carcinomatous meningitis * Presence or history of a malignant disease other than NSCLC that had been diagnosed and/or required therapy within the past 3 years * Presence or history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis * Long QT syndrome, …